Drug Profile
Antisense K-ras RNA gene therapy - Silenseed
Alternative Names: KRASG12D-LODER; siG12D-LODERLatest Information Update: 14 Dec 2023
Price :
$50
*
At a glance
- Originator Silenseed
- Class Antineoplastics; Gene therapies
- Mechanism of Action KRAS protein modulators; Ras gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pancreatic cancer
Most Recent Events
- 20 Oct 2023 Efficacy and adverse events data from a phase II PROTACT trial in Pancreatic cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 28 Sep 2021 Phase-II development is ongoing in USA and Israel (NCT01676259)
- 07 Mar 2018 Phase-II clinical trials in Pancreatic cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease) in Israel (Intratumoural) (NCT01676259)